A 2025 IRB-approved pilot study published in PubMed reported no adverse effects following intravenous administration of 20mg in 2 healthy adults, with monitored biomarkers (heart, liver, kidneys, thyroid, and blood glucose) returning normal results
Market Opportunity: No FDA-approved treatments for babesiosis Estimated $245M peak annual sales and up to $1.1B potential revenue over 10 years Trials continuing at top-tier U.S
The primary mechanisms of action include: Enhancing glucose-dependent insulin secretion from pancreatic beta cells, which helps lower blood glucose levels when they are elevated Suppressing glucagon release from pancreatic alpha cells, reducing hepatic glucose production [1] [2] Slowing gastric emptying , which moderates the rate at which nutrients enter the bloodstream Promoting satiety through central nervous system pathways, leading to reduced caloric intake [1] [2] These medications are peptide-based (and one fusion protein) and are temperature sensitive
Because peptides are fragile, the way you handle them during the mixing process determines whether the medication remains active or becomes denatured, which means it loses its structure and effectiveness